Trial register facet
Reported trial records — page 7
644 records with the status reported.
Showing 0 records on this page
Records
644 documents · page 7 of 27
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURMOUNT-2-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-QOLprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| OASIS-1-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| RETA-PH2-OBESITY-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-T2D-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-OBESITY-QOLprogramme record | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| ORFO-PH2-T2D-PKprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-JPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-QOLprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY-REGIONAL-JPprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-REGIONAL-CNprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| OASIS-1-ADHERENCEprogramme record | Semaglutide, oral | Phase 3 | Reported | Observational | — | 2023 | Very low |
| RETA-PH2-OBESITY-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-OBESITY-REGIONAL-CNprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-BODY-COMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| RETA-PH2-T2D-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| STEP-5 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 304 | 2022 | High |
| STEP-8 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 338 | 2022 | High |
| STEP-TEENS | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 201 | 2022 | Moderate |
| SURMOUNT-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,539 | 2022 | High |
| SURPASS-5 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 475 | 2022 | High |
page 7 of 27